Coloring books are no longer just for kids. They are a hot trend for adults who find that coloring between the lines is a relaxing, creative outlet in our ever-more frenzied times. Artist Tiffany Zimmerman, who is always seeking to expand her horizons, decided to design one for people like herself who depend on a… Read More »
A coloring book for the mobility challenged
New genetic test being developed for FSHD
From Globe Newswire Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets the Saphyr® system, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, today announced that leading organizations, including PerkinElmer Genomics and the University of Iowa, have adopted Saphyr for use in their clinical genomics laboratories. … Read More »
Tax advantages from ABLE accounts
You may not even know you are eligible for these By Chris Stenmon, CPA, Braintree, Massachusetts Some consider this the most significant federal legislation for disabled individuals since President George H. W. Bush signed the Americans with Disabilities Act (ADA) into law in 1990. Called the Stephen Beck, Jr. Achieving a Better Life Experience (ABLE)… Read More »
FSHD Gene May Help Tumors Evade the Immune System
BY ALEXANDRA BELAYEW, MONS, BELGIUM DUX4, the gene that plays a key role in facioscapulohumeral muscular dystrophy (FSHD), is gaining unexpected notoriety in cancer research. According to a recent study1 from the Fred Hutchinson Cancer Research Center in Seattle, Washington, gene mutations in tumor cells can cause a re-expression of DUX4 in malignant tissues. What’s… Read More »
Fulcrum Announced Results of Phase 1 Clinical Trial of Losmapimod
Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target engagement of losmapimod in patients with facioscapulohumeral dystrophy. CAMBRIDGE, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced preliminary… Read More »